Effect of RTS,S/AS01_E vaccine booster dose on cellular immune responses in African infants and children.

ABSTRACT: RTS,S/AS01_E, the first approved malaria vaccine, demonstrated moderate efficacy during the phase 3 pediatric trial. We previously investigated cell-mediated immune (CMI) responses following the primary 3-dose immunization and now report responses to the booster dose given 18 months later. Thirty CMI markers were measured by Luminex in supernatants of peripheral blood mononuclear cells from 709 children and infants after RTS,S/AS01_E antigen stimulation, and their associations with malaria risk and antibodies one month post-booster and one year later were assessed. IL-2, IFN-γ, IL-17, IL-5, and IL-13 were associated with RTS,S/AS01_E booster vaccination, and IL-2 responses to the circumsporozoite protein (CSP) remained higher after one year. IL-2 was associate

SUBMITTER: Mitchell RA 

PROVIDER: S-EPMC11511852 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature